,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2018-10-11 04:31:00,The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch .,0.05701610818505287,0.005183438304811716,0.937800407409668,neutral,0.051832668483257294
1,2018-10-11 04:31:00,This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.,0.44832858443260193,0.01002567633986473,0.5416457653045654,neutral,0.4383029043674469
2,2018-10-11 04:31:00,"AMGEN, INC. ( AMGN ) is a large-cap growth stock in the Biotechnology & Drugs industry.",0.6231282949447632,0.009882195852696896,0.36698949337005615,positive,0.6132460832595825
3,2018-10-11 04:31:00,The rating according to our strategy based on Peter Lynch changed from 72% to 91% based on the firm's underlying fundamentals and the stock's valuation.,0.4713962972164154,0.01844373717904091,0.510159969329834,neutral,0.4529525637626648
4,2018-10-11 04:31:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
5,2018-10-11 04:31:00,Company Description: Amgen Inc. is a biotechnology company.,0.012834355235099792,0.008020137436687946,0.9791455268859863,neutral,0.004814217798411846
6,2018-10-11 04:31:00,"The Company discovers, develops, manufactures and delivers various human therapeutics.",0.04877732694149017,0.004117672797292471,0.9471049308776855,neutral,0.044659655541181564
7,2018-10-11 04:31:00,It operates in human therapeutics segment.,0.03858906030654907,0.005032994784414768,0.9563779234886169,neutral,0.03355606645345688
8,2018-10-11 04:31:00,"Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).",0.017958298325538635,0.006075523793697357,0.975966215133667,neutral,0.011882774531841278
9,2018-10-11 04:31:00,"It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience.",0.023292776197195053,0.005788520444184542,0.9709186553955078,neutral,0.0175042562186718
10,2018-10-11 04:31:00,"Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.",0.07398897409439087,0.007534234784543514,0.9184767603874207,neutral,0.06645473837852478
11,2018-10-11 04:31:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
12,2018-10-11 04:31:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
13,2018-10-11 04:31:00,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

AGILENT TECHNOLOGIES INC ( A ) is a large-cap growth stock in the Scientific & Technical Instr.",0.12218917161226273,0.006553479935973883,0.8712573647499084,neutral,0.1156356930732727
14,2018-10-11 04:31:00,industry.,0.05218227207660675,0.023317871615290642,0.9244998097419739,neutral,0.02886440046131611
15,2018-10-11 04:31:00,The rating according to our strategy based on Peter Lynch changed from 87% to 94% based on the firm's underlying fundamentals and the stock's valuation.,0.45084676146507263,0.018099768087267876,0.5310534834861755,neutral,0.4327470064163208
16,2018-10-11 04:31:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
17,2018-10-11 04:31:00,"Company Description: Agilent Technologies, Inc. provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.",0.03528047353029251,0.005012430250644684,0.9597071409225464,neutral,0.030268043279647827
18,2018-10-11 04:31:00,"The Company serves the life sciences, diagnostics and applied chemical markets.",0.02533106692135334,0.004966375418007374,0.9697026014328003,neutral,0.02036469057202339
19,2018-10-11 04:31:00,"It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.",0.016505418345332146,0.006693211384117603,0.9768013954162598,neutral,0.009812206961214542
20,2018-10-11 04:31:00,"Its life sciences and applied markets business segment offers instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level.",0.07263351231813431,0.004264696501195431,0.9231017827987671,neutral,0.0683688148856163
21,2018-10-11 04:31:00,"Its diagnostics and genomics business segment includes the reagent partnership, pathology, companion diagnostics, genomics and the nucleic acid solutions businesses.",0.016729282215237617,0.006404377520084381,0.9768663048744202,neutral,0.010324904695153236
22,2018-10-11 04:31:00,Its Agilent CrossLab business segment spans the entire lab with its consumables and services portfolio.,0.040530722588300705,0.004760046489536762,0.9547092318534851,neutral,0.03577067703008652
23,2018-10-11 04:31:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
24,2018-10-11 04:31:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
25,2018-10-11 04:31:00,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

BAXTER INTERNATIONAL INC ( BAX ) is a large-cap growth stock in the Medical Equipment & Supplies industry.",0.5010000467300415,0.009393168613314629,0.48960670828819275,positive,0.4916068911552429
26,2018-10-11 04:31:00,The rating according to our strategy based on Peter Lynch changed from 87% to 91% based on the firm's underlying fundamentals and the stock's valuation.,0.4656260311603546,0.018128445371985435,0.5162454843521118,neutral,0.44749757647514343
27,2018-10-11 04:31:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
28,2018-10-11 04:31:00,"Company Description: Baxter International Inc., through its subsidiaries, provides renal and hospital products.",0.016776859760284424,0.00666993809863925,0.9765532612800598,neutral,0.010106921195983887
29,2018-10-11 04:31:00,The Company operates through two segments: Hospital Products and Renal.,0.015520949847996235,0.00666307145729661,0.9778159856796265,neutral,0.008857877925038338
30,2018-10-11 04:31:00,"Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.",0.023244887590408325,0.005879237316548824,0.9708758592605591,neutral,0.017365649342536926
31,2018-10-11 04:31:00,"The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis ( HD ), continuous renal replacement therapy (CRRT) and additional dialysis services.",0.13980115950107574,0.004776298999786377,0.8554225564002991,neutral,0.13502486050128937
32,2018-10-11 04:31:00,"Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.",0.01395258679986,0.007541074883192778,0.9785063862800598,neutral,0.006411511916667223
33,2018-10-11 04:31:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
34,2018-10-11 04:31:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
35,2018-10-11 04:31:00,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

DELUXE CORPORATION (DLX) is a mid-cap value stock in the Computer Services industry.",0.05222798511385918,0.008106691762804985,0.9396652579307556,neutral,0.04412129521369934
36,2018-10-11 04:31:00,The rating according to our strategy based on Peter Lynch changed from 72% to 76% based on the firm's underlying fundamentals and the stock's valuation.,0.4703299105167389,0.018794206902384758,0.5108758807182312,neutral,0.451535701751709
37,2018-10-11 04:31:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
38,2018-10-11 04:31:00,Company Description: Deluxe Corporation is a provider of payment solutions.,0.024949463084340096,0.005557732190936804,0.9694927930831909,neutral,0.019391730427742004
39,2018-10-11 04:31:00,The Company provides a suite of customer life cycle management solutions to its customers across multiple channels.,0.0950876846909523,0.0048262993805110455,0.900085985660553,neutral,0.09026138484477997
40,2018-10-11 04:31:00,"The Company operates in three segments: Small Business Services segment, Financial Services segment and Direct Checks segment.",0.015019936487078667,0.00716143986210227,0.9778186082839966,neutral,0.00785849615931511
41,2018-10-11 04:31:00,"The Company's product and service offerings consist of checks, forms and accessories, and other products.",0.013332425616681576,0.006256026681512594,0.9804115295410156,neutral,0.0070763989351689816
42,2018-10-11 04:31:00,The forms offered by the Company include deposit tickets and check registers.,0.01226288452744484,0.007632529828697443,0.9801045656204224,neutral,0.0046303546987473965
43,2018-10-11 04:31:00,Its accessories and other products include checkbook covers and stamps.,0.02107863873243332,0.0065569463185966015,0.9723643660545349,neutral,0.01452169194817543
44,2018-10-11 04:31:00,The Small Business Services segment is a provider of printed forms to small businesses.,0.014156161807477474,0.006886905990540981,0.9789569973945618,neutral,0.007269255816936493
45,2018-10-11 04:31:00,The Financial Services segment provides products and services to financial institution clients and offers a suite of financial technology (FinTech) solutions.,0.05282234400510788,0.004195604007691145,0.9429820775985718,neutral,0.04862673953175545
46,2018-10-11 04:31:00,The Direct Checks segment is a direct-to-consumer check supplier.,0.020302508026361465,0.0057084825821220875,0.9739890098571777,neutral,0.014594025909900665
47,2018-10-11 04:31:00,"It also offers fraud protection and security services, online and offline payroll services, and electronic checks (e-checks).",0.014810516498982906,0.009161114692687988,0.9760284423828125,neutral,0.005649401806294918
48,2018-10-11 04:31:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
49,2018-10-11 04:31:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
50,2018-10-11 04:31:00,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

REPUBLIC FIRST BANCORP, INC. (FRBK) is a small-cap growth stock in the Regional Banks industry.",0.41703641414642334,0.010132156312465668,0.5728314518928528,neutral,0.4069042503833771
51,2018-10-11 04:31:00,The rating according to our strategy based on Peter Lynch changed from 81% to 96% based on the firm's underlying fundamentals and the stock's valuation.,0.46090805530548096,0.01703861728310585,0.5220533609390259,neutral,0.4438694417476654
52,2018-10-11 04:31:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
53,2018-10-11 04:31:00,"Company Description: Republic First Bancorp, Inc. is a holding company for Republic First Bank (Republic or the Bank), which does business under the name Republic Bank.",0.016494860872626305,0.007669863756746054,0.9758352637290955,neutral,0.008824996650218964
54,2018-10-11 04:31:00,"The Company's community banking segment encompasses the commercial loan and deposit activities of Republic, as well as consumer loan products in the areas surrounding its store network.",0.016590682789683342,0.00560581823810935,0.9778035283088684,neutral,0.010984864085912704
55,2018-10-11 04:31:00,"The Company offers a range of banking products and services, including consumer and commercial deposit accounts, checking accounts, interest-bearing demand accounts, money market accounts, certificates of deposit, savings accounts, sweep accounts, lockbox services and individual retirement accounts (and other traditional banking services), secured and unsecured commercial loans, real estate loans, construction and land development loans, automobile loans, home improvement loans, mortgages, home equity and overdraft lines of credit, and other products.",0.02252349816262722,0.005068723578006029,0.9724077582359314,neutral,0.01745477505028248
56,2018-10-11 04:31:00,The Bank offers a range of credit and depository banking services.,0.03953046724200249,0.004058360122144222,0.9564111828804016,neutral,0.03547210618853569
57,2018-10-11 04:31:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
58,2018-10-11 04:31:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
59,2018-10-11 04:31:00,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

AXA SA (ADR) (AXAHY) is a large-cap value stock in the Insurance (Life) industry.",0.0684056282043457,0.005722487345337868,0.9258719086647034,neutral,0.06268314272165298
60,2018-10-11 04:31:00,The rating according to our strategy based on Peter Lynch changed from 81% to 100% based on the firm's underlying fundamentals and the stock's valuation.,0.49302399158477783,0.016259171068668365,0.4907167851924896,positive,0.47676482796669006
61,2018-10-11 04:31:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
62,2018-10-11 04:31:00,Company Description: AXA SA (AXA) is a France-based holding company engaged in the business of financial protection.,0.019650952890515327,0.006057313643395901,0.9742917418479919,neutral,0.013593639247119427
63,2018-10-11 04:31:00,"The Company's segments include Life & Savings, Property & Casualty, Asset Management , Banking and Holding companies.",0.016151491552591324,0.00582442432641983,0.9780240058898926,neutral,0.010327067226171494
64,2018-10-11 04:31:00,"The Life & Savings segment's products include a range of investment and savings products, as well as Protection and Health products.",0.017593201249837875,0.005311014596372843,0.9770958423614502,neutral,0.01228218711912632
65,2018-10-11 04:31:00,"The Property & Casualty segment includes a range of products, including mainly motor, household, property and general liability insurance.",0.01893598958849907,0.0050055463798344135,0.9760584831237793,neutral,0.013930443674325943
66,2018-10-11 04:31:00,The Asset Management segment includes diversified asset management (including investment fund management) and related services.,0.018431518226861954,0.005280411336570978,0.9762880802154541,neutral,0.013151107355952263
67,2018-10-11 04:31:00,"The Banking segment includes banking activities (retail banking, mortgage loans and savings) conducted in France, Belgium and Germany.",0.010631119832396507,0.008017503656446934,0.981351375579834,neutral,0.0026136161759495735
68,2018-10-11 04:31:00,The Holding companies segment includes all non-operational activities.,0.00919042993336916,0.008863845840096474,0.9819456934928894,neutral,0.000326584093272686
69,2018-10-11 04:31:00,It also operates through Maestro Health.,0.027798647060990334,0.004962596110999584,0.96723872423172,neutral,0.022836051881313324
70,2018-10-11 04:31:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
71,2018-10-11 04:31:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
72,2018-10-11 04:31:00,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

KENNAMETAL INC. (KMT) is a mid-cap value stock in the Misc.",0.011081560514867306,0.012659727595746517,0.9762586355209351,neutral,-0.0015781670808792114
73,2018-10-11 04:31:00,Capital Goods industry.,0.021840866655111313,0.007956510409712791,0.9702026844024658,neutral,0.013884356245398521
74,2018-10-11 04:31:00,The rating according to our strategy based on Peter Lynch changed from 72% to 76% based on the firm's underlying fundamentals and the stock's valuation.,0.4703299105167389,0.018794206902384758,0.5108758807182312,neutral,0.451535701751709
75,2018-10-11 04:31:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
76,2018-10-11 04:31:00,"Company Description: Kennametal Inc. is a supplier of tooling, engineered components and materials consumed in production processes.",0.02306242845952511,0.005509485490620136,0.9714280962944031,neutral,0.017552942037582397
77,2018-10-11 04:31:00,The Company operates through two segments: Industrial and Infrastructure.,0.01566767878830433,0.005860804580152035,0.978471577167511,neutral,0.009806874208152294
78,2018-10-11 04:31:00,"The Industrial segment generally serves customers that operate in industrial end markets, such as transportation, general engineering, aerospace and defense.",0.0166039876639843,0.005641303025186062,0.9777546525001526,neutral,0.010962684638798237
79,2018-10-11 04:31:00,"The Infrastructure segment generally serves customers that operate in the earthworks and energy sectors supporting primary industries, such as oil and gas, power generation, underground, surface and hard-rock mining, highway construction and road maintenance.",0.018511643633246422,0.005698439199477434,0.9757899045944214,neutral,0.012813204899430275
80,2018-10-11 04:31:00,"It provides wear-resistant products, application engineering and services backed by material science serving customers across various sectors.",0.03966987878084183,0.004297122824937105,0.9560329914093018,neutral,0.03537275642156601
81,2018-10-11 04:31:00,"The Company's product offerings include a selection of standard and customized technologies for metalworking, such as metal cutting tools, tooling systems and services, as well as materials, such as cemented tungsten carbide products and super alloys.",0.041181739419698715,0.00403547240421176,0.9547827839851379,neutral,0.03714626654982567
82,2018-10-11 04:31:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
83,2018-10-11 04:31:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
84,2018-10-11 04:31:00,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

KLA-TENCOR CORP (KLAC) is a large-cap value stock in the Semiconductors industry.",0.0769529938697815,0.005555891897529364,0.91749107837677,neutral,0.07139710336923599
85,2018-10-11 04:31:00,The rating according to our strategy based on Peter Lynch changed from 74% to 93% based on the firm's underlying fundamentals and the stock's valuation.,0.41090214252471924,0.017899056896567345,0.5711987614631653,neutral,0.39300307631492615
86,2018-10-11 04:31:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
87,2018-10-11 04:31:00,Company Description: KLA-Tencor Corporation (KLA-Tencor) is a supplier of process control and yield management solutions for the semiconductor and related nanoelectronics industries.,0.05487436428666115,0.005928873550146818,0.939196765422821,neutral,0.04894549027085304
88,2018-10-11 04:31:00,"The Company's products are also used in a number of other high technology industries, including the light emitting diode (LED) and data storage industries, as well as general materials research.",0.04998026043176651,0.004427201114594936,0.9455925822257996,neutral,0.045553058385849
89,2018-10-11 04:31:00,"Its products and services are used by bare wafer, integrated circuit (IC), lithography reticle (reticle or mask) and disk manufacturers around the world.",0.02863694727420807,0.004834250081330538,0.9665288329124451,neutral,0.02380269765853882
90,2018-10-11 04:31:00,"The Company's inspection and metrology products and related offerings are categorized in various groups, including Chip Manufacturing, Wafer Manufacturing, Reticle Manufacturing, LED, Power Device and Compound Semiconductor Manufacturing, Data Storage Media/Head Manufacturing, Microelectromechanical Systems (MEMS) Manufacturing, and General Purpose/Lab Applications.",0.015164337120950222,0.006657193880528212,0.9781784415245056,neutral,0.008507143706083298
91,2018-10-11 04:31:00,It also provides refurbished KLA-Tencor tools as service and support for its products.,0.049593377858400345,0.005609377287328243,0.9447972178459167,neutral,0.04398399963974953
92,2018-10-11 04:31:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
93,2018-10-11 04:31:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
94,2018-10-11 04:31:00,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

Since its inception, Validea's strategy based on Peter Lynch has returned -34.87% vs. 178.45% for the S&P 500.",0.6836577653884888,0.2748100161552429,0.0415322482585907,positive,0.40884774923324585
95,2018-10-11 04:31:00,"For more details on this strategy, click here

About Peter Lynch : Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time.",0.8456207513809204,0.014854133129119873,0.13952510058879852,positive,0.8307666182518005
96,2018-10-11 04:31:00,Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street.,0.38180962204933167,0.017028477042913437,0.6011618971824646,neutral,0.36478114128112793
97,2018-10-11 04:31:00,"(""Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it,"" is one of his many pearls of wisdom.)",0.06574074923992157,0.02636720798909664,0.9078919887542725,neutral,0.03937353938817978
98,2018-10-11 04:31:00,"Lynch's bestseller One Up on Wall Street is something of a ""stocks for the everyman/everywoman"", breaking his approach down into easy-to-understand concepts.",0.17277808487415314,0.0457223504781723,0.7814995646476746,neutral,0.12705573439598083
99,2018-10-11 04:31:00,About Validea : Validea is an investment research service that follows the published strategies of investment legends.,0.01593991555273533,0.006665502674877644,0.9773945808410645,neutral,0.009274412877857685
100,2018-10-11 04:31:00,"Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig.",0.08751807361841202,0.010206559672951698,0.9022754430770874,neutral,0.07731151580810547
101,2018-10-11 04:31:00,"For more information about Validea, click here

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.009221813641488552,0.018771808594465256,0.9720064401626587,neutral,-0.009549994952976704
